3-Feb-2025 8:00 AM CST - Business Wire Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Companys website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. E
27-Nov-2024 8:00 AM CST - Business Wire Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, in Coral Gables, Florida on Wednesday, December 4, 2024, at 8:20 a.m. ET. A webcast of the fireside chat will be available through the Investors and Media section of Gerons website under Events following the presentation. The
11-Nov-2024 8:00 AM CST - Business Wire Geron to Participate in the Stifel 2024 Healthcare Conference Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a fireside chat at the Stifel 2024 Healthcare Conference, in New York City, on Monday, November 18th, 2024, at 1:50pm ET. A webcast of the fireside chat will be available through the Investors and Media section of Gerons website under Events following the presentation. The webcast will be archived an
7-Nov-2024 6:00 AM CST - Business Wire Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2024 and recent business highlights. This has been a transformative year for Geron, following our first FDA approval and commercial launch of RYTELO in June. The initial full quarter of product revenue from our U.S. launch exceeded our expectations and demonst
15-Oct-2024 3:30 PM CST - Business Wire Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the market opens on Thursday, November 7, 2024 via press release, which will be available on the Companys website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A
3-Feb-2025 8:00 AM CST - Business Wire Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Companys website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. E
27-Nov-2024 8:00 AM CST - Business Wire Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, in Coral Gables, Florida on Wednesday, December 4, 2024, at 8:20 a.m. ET. A webcast of the fireside chat will be available through the Investors and Media section of Gerons website under Events following the presentation. The
11-Nov-2024 8:00 AM CST - Business Wire Geron to Participate in the Stifel 2024 Healthcare Conference Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a fireside chat at the Stifel 2024 Healthcare Conference, in New York City, on Monday, November 18th, 2024, at 1:50pm ET. A webcast of the fireside chat will be available through the Investors and Media section of Gerons website under Events following the presentation. The webcast will be archived an
7-Nov-2024 6:00 AM CST - Business Wire Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2024 and recent business highlights. This has been a transformative year for Geron, following our first FDA approval and commercial launch of RYTELO in June. The initial full quarter of product revenue from our U.S. launch exceeded our expectations and demonst
15-Oct-2024 3:30 PM CST - Business Wire Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024 Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the market opens on Thursday, November 7, 2024 via press release, which will be available on the Companys website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A